Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;17(1):55-69.
doi: 10.1007/s13311-019-00814-4.

Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA

Amanda J Abraham  1 , Christina M Andrews  2 , Samantha J Harris  3 , Peter D Friedmann  4
Affiliations
Review

Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA

Amanda J Abraham et al. Neurotherapeutics. 2020 Jan.

Abstract

Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medications in the specialty substance use disorder treatment system, other treatment settings and systems, and among providers with a federal waiver to prescribe buprenorphine. We also present the most current data on the availability of alcohol and opioid use disorder medications in the USA. These estimates show steady growth in availability of opioid use disorder medications over the past decade and a decline in availability of alcohol use disorder medications. However, overall use of medications in the USA remains low. In 2017, only 16.3% of specialty treatment programs offered any single medication for alcohol use disorder treatment and 35.5% offered any single medication for opioid use disorder treatment. Availability of buprenorphine-waivered providers has increased significantly since 2002. However, geographic disparities in access to buprenorphine remain. Some of the most promising strategies to increase availability of alcohol and opioid use disorder medications include the following: incorporating substance use disorder training in healthcare education programs, educating the substance use disorder workforce about the benefits of medication treatment, reducing stigma surrounding the use of medications, implementing medications in primary care settings, implementing integrated care models, revising regulations on methadone and buprenorphine, improving health insurance coverage of medications, and developing novel medications for the treatment of substance use disorder.

Keywords: Alcohol use disorder; buprenorphine-waivered providers.; medication treatment; opioid use disorder; specialty treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Substance Abuse and Mental Health Services Administration . Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.
    1. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the united states, 2013. Med Care. 2016;54(10):901–6. doi: 10.1097/MLR.0000000000000625. - DOI - PMC - PubMed
    1. Ahmad F, Rossen L, Spencer M, Warner M, Sutton P. Provisional drug overdose death counts; 2018. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed 1 June 2019
    1. Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD. 2010 National and State Costs of Excessive Alcohol Consumption. Am J Prev Med. 2015;49(5):e73–e9. doi: 10.1016/j.amepre.2015.05.031. - DOI - PubMed
    1. Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;11:E109. doi: 10.5888/pcd11.130293. - DOI - PMC - PubMed

MeSH terms